A Phase III clinical study switching paroxysmal nocturnal hemoglobinuria (PNH) patients from eculizumab treatment to Coversin

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Oct 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nomacopan (Primary) ; Eculizumab
Indications Paroxysmal nocturnal haemoglobinuria
Focus Therapeutic Use
Acronyms ASSET

Most Recent Events

30 Sep 2018 Status changed from planning to recruiting, according to an Akari Therapeutics media release.
06 Feb 2018 According to an Akari media release, company plans to initiate this trial in the end of first quarter of 2018.
08 Dec 2017 According to an Akari media release, company plans to initiate this trial in the second half of 2018 and will include Soliris switch patients.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight